Polatuzumab Vedotin-Based Salvage Chemotherapy in the Third-Line or Above Treatment for Diffuse Large B-Cell Lymphoma
Journal
Blood
Journal Volume
136
Journal Issue
Supplement 1
Start Page
12-12
ISSN
0006-4971
1528-0020
Date Issued
2020-11-05
Author(s)
Jia-Hau Liu
Yu-Wen Wang
LI-CHUN LU
Abstract
Disclosures
Tsai: Novartis: Honoraria, Membership on an entity's Board of Directors or advisory committees; Chugai: Honoraria; Harvester: Honoraria; Janssen: Honoraria; Kirin: Honoraria; Takeda: Honoraria; BMS: Honoraria; Astellas: Honoraria; Pfizer: Honoraria, Membership on an entity's Board of Directors or advisory committees; Celgene: Honoraria, Research Funding; Roche: Honoraria, Membership on an entity's Board of Directors or advisory committees. Ko:Roche: Honoraria. Cheng:Roche: Honoraria. Huang:MundiPharma: Honoraria; Chugai: Honoraria; Roche: Membership on an entity's Board of Directors or advisory committees; Novartis: Honoraria; Janssen: Honoraria; Takeda: Honoraria; Bristol Meyer & Squibb: Honoraria.
SDGs
Publisher
American Society of Hematology
Type
journal article